Chengdu CoenBiotech

CoenBiotech is a clinical-stage biopharmaceutical company headquartered in Chengdu, China, specializing in the discovery and development of small molecule therapeutics for autoimmune diseases and oncology. The company's lead program, CN001, is a highly selective Tyrosine kinase 2 (TYK2) inhibitor currently undergoing Phase 2 clinical trials for indications such as plaque psoriasis. CoenBiotech leverages its expertise in medicinal chemistry to develop a pipeline of candidates targeting the JAK/STAT signaling pathway and other validated biological targets. Beyond dermatology, the company is exploring the potential of its lead assets in systemic lupus erythematosus and inflammatory bowel disease. The firm aims to provide safer and more effective oral treatment options for patients with chronic inflammatory conditions who have limited therapeutic choices.